Brief: IMUNON Says First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001

Imunon

18/10/2023 13:33

Oct 18 (Reuters) - Imunon Inc  IMNN.O :
    * IMUNON ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 1/2
CLINICAL
TRIAL OF IMNN-001 IN COMBINATION WITH BEVACIZUMAB IN ADVANCED
OVARIAN CANCER
    * IMUNON INC - PHASE 1/2 TRIAL IS EXPECTED TO ENROLL 50
PATIENTS
WITH STAGE III/IV ADVANCED OVARIAN CANCER

Source text for Eikon:  ID:nGNX3VZkh2 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))